Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants
NCT ID: NCT00899457
Last Updated: 2014-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
37 participants
OBSERVATIONAL
2008-04-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is looking for molecular markers in predicting lung cancer development using tissue samples from healthy participants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
NCT00899028
Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
NCT01139944
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
NCT01414595
Detection of Genetic Markers of Lung Cancer
NCT00280202
Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy Volunteers
NCT00899262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To obtain biological specimens from healthy participants with no known risk of lung cancer to use as controls in the study of lung cancer progression.
* To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung.
OUTLINE: Serum, urine, sputum, and buccal cell samples are collected. Patients also undergo bronchoscopy for collection of bronchial tissue and bronchial brush samples. The samples are used for genomic and proteomic studies to identify new molecular abnormalities specific to the development of lung cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy, non-smokers
proteomic profiling
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
biologic sample preservation procedure
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
laboratory biomarker analysis
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
bronchoscopy
Collection of breath condensate.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
proteomic profiling
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
biologic sample preservation procedure
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
laboratory biomarker analysis
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
bronchoscopy
Collection of breath condensate.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy participant
* No history of smoking
* No history of cancer
PATIENT CHARACTERISTICS:
* SWOG performance status 0
* No clinically apparent bleeding diathesis
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pierre P. Massion, MD
Associate Professor of Medicine (Allergy, Pulmonary & Critical Care) and Cancer Biology; Pulmonary and Critical Care Medicine Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre P. Massion, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VU-VICC-THO-0734
Identifier Type: -
Identifier Source: secondary_id
VICC-THO-0734
Identifier Type: -
Identifier Source: secondary_id
VICC THO 0734
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.